<p>你可能会认为，<strong>XOMA Royalty Corporation</strong>（NASDAQ:XOMA）以 6.6 倍的市销率（或称&#34;P/S&#34;）值得关注，因为几乎一半的美国生物科技公司市销率超过 12.1 倍，甚至市销率高达 93 倍的情况也并不罕见。然而，市销率低可能是有原因的，需要进一步调查以确定这种情况是否合理。</p>
<p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整名单，免费获取。</p>
<p>查看我们对 XOMA Royalty 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/36769-ps-multiple-vs-industry-1-dark-2/1765825294722?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/36769-ps-multiple-vs-industry-1-dark-2/1765825294722"/></p>
<p>纳斯达克 GM:XOMA 市销率与行业对比 2025 年 12 月 15 日</p>
<h3>XOMA Royalty 的表现如何</h3>
<p>XOMA Royalty 的表现可能更好，因为它的收入增长低于大多数其他公司。也许市场预计当前的收入增长疲软趋势将持续，这使得市销率受到压制。如果是这样，现有股东可能会对股价未来的走势感到失望。</p>
<p>想知道分析师如何看待 XOMA Royalty 的未来与行业的对比吗？在这种情况下，我们的 <strong>免费</strong> 报告是一个很好的起点。</p>
<h2>XOMA Royalty 是否有收入增长的预测？</h2>
<p>你唯一会真正感到舒适的情况是，当公司的增长预计将落后于行业时，看到像 XOMA Royalty 这样的低市销率。</p>
<p>回顾过去一年，公司收入实现了 118% 的显著增长。最近三年期间，收入整体增长了 16%，这在很大程度上得益于其短期表现。因此，可以公平地说，最近公司的收入增长是相当可观的。</p>
<p>展望未来，覆盖该公司的五位分析师的估计显示，未来三年收入预计每年增长 40%。这明显低于更广泛行业预期的 132% 的年增长率。</p>
<p>鉴于此，XOMA Royalty 的市销率低于大多数其他公司是可以理解的。似乎大多数投资者预计未来增长有限，因此只愿意为该股票支付较低的价格。</p>
<h2>最后的总结</h2>
<p>虽然市销率不应成为你是否购买股票的决定性因素，但它是收入预期的一个相当有效的晴雨表。</p>
<p>我们已经确定，XOMA Royalty 维持其低市销率是因为其预测增长低于更广泛行业的预期。在这个阶段，投资者认为收入改善的潜力不足以证明更高的市销率。公司需要运气的改变才能在未来证明市销率的上升是合理的。</p>
<p>还值得注意的是，我们发现 <strong>XOMA Royalty 有 2 个警示信号</strong>，你需要考虑。</p>
<p>如果你对盈利的强大公司感兴趣，那么你会想查看这份 <strong>免费</strong> 的有趣公司名单，这些公司以低市盈率交易（但已证明它们能够增长盈利）。</p>
<p>国防和灾难的移动基础设施</p>
<p>下一波机器人技术不是类人型的。它是完全自主的塔楼，在 30 分钟内提供 5G、ISR 和雷达，随时随地。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>代表 CiTech 赞助</p>

标记临床研究

<p>XOMA Royalty Corporation（纳斯达克代码：XOMA）的市销率（P/S）为 6.6 倍，低于行业平均水平。这是由于其收入增长速度低于更广泛的生物科技行业。分析师预测，XOMA 在未来三年的年收入增长率为 40%，低于行业 132% 的增长预测。投资者持谨慎态度，预计未来增长有限，因此该股票的市销率保持在低位。公司需要显著改善，以证明其更高的市销率的合理性</p>

<p>You may think that with a price-to-sales (or &#34;P/S&#34;) ratio of 6.6x <strong>XOMA Royalty Corporation</strong> (NASDAQ:XOMA) is a stock worth checking out, seeing as almost half of all the Biotechs companies in the United States have P/S ratios greater than 12.1x and even P/S higher than 93x aren't out of the ordinary. However, the P/S might be low for a reason and it requires further investigation to determine if it's justified.</p>
<div class="lb-trans"><p>你可能会认为，<strong>XOMA Royalty Corporation</strong>（NASDAQ:XOMA）以 6.6 倍的市销率（或称&#34;P/S&#34;）值得关注，因为几乎一半的美国生物科技公司市销率超过 12.1 倍，甚至市销率高达 93 倍的情况也并不罕见。然而，市销率低可能是有原因的，需要进一步调查以确定这种情况是否合理。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整名单，免费获取。</p>
</div><p>Check out our latest analysis for XOMA Royalty</p>
<div class="lb-trans"><p>查看我们对 XOMA Royalty 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/36769-ps-multiple-vs-industry-1-dark-2/1765825294722" alt="" original-src="https://images.simplywall.st/asset/chart/36769-ps-multiple-vs-industry-1-dark-2/1765825294722"/></p>
<p>NasdaqGM:XOMA Price to Sales Ratio vs Industry December 15th 2025</p>
<div class="lb-trans"><p>纳斯达克 GM:XOMA 市销率与行业对比 2025 年 12 月 15 日</p>
</div><h3>How XOMA Royalty Has Been Performing</h3>
<div class="lb-trans"><h3>XOMA Royalty 的表现如何</h3>
</div><p>XOMA Royalty could be doing better as it's been growing revenue less than most other companies lately. Perhaps the market is expecting the current trend of poor revenue growth to continue, which has kept the P/S suppressed. If this is the case, then existing shareholders will probably struggle to get excited about the future direction of the share price.</p>
<div class="lb-trans"><p>XOMA Royalty 的表现可能更好，因为它的收入增长低于大多数其他公司。也许市场预计当前的收入增长疲软趋势将持续，这使得市销率受到压制。如果是这样，现有股东可能会对股价未来的走势感到失望。</p>
</div><p>Keen to find out how analysts think XOMA Royalty's future stacks up against the industry? In that case, our <strong>free</strong> report is a great place to start.</p>
<div class="lb-trans"><p>想知道分析师如何看待 XOMA Royalty 的未来与行业的对比吗？在这种情况下，我们的 <strong>免费</strong> 报告是一个很好的起点。</p>
</div><h2>Is There Any Revenue Growth Forecasted For XOMA Royalty?</h2>
<div class="lb-trans"><h2>XOMA Royalty 是否有收入增长的预测？</h2>
</div><p>The only time you'd be truly comfortable seeing a P/S as low as XOMA Royalty's is when the company's growth is on track to lag the industry.</p>
<div class="lb-trans"><p>你唯一会真正感到舒适的情况是，当公司的增长预计将落后于行业时，看到像 XOMA Royalty 这样的低市销率。</p>
</div><p>Retrospectively, the last year delivered an exceptional 118% gain to the company's top line. The latest three year period has also seen a 16% overall rise in revenue, aided extensively by its short-term performance. Therefore, it's fair to say the revenue growth recently has been respectable for the company.</p>
<div class="lb-trans"><p>回顾过去一年，公司收入实现了 118% 的显著增长。最近三年期间，收入整体增长了 16%，这在很大程度上得益于其短期表现。因此，可以公平地说，最近公司的收入增长是相当可观的。</p>
</div><p>Shifting to the future, estimates from the five analysts covering the company suggest revenue should grow by 40% per annum over the next three years. That's shaping up to be materially lower than the 132% per year growth forecast for the broader industry.</p>
<div class="lb-trans"><p>展望未来，覆盖该公司的五位分析师的估计显示，未来三年收入预计每年增长 40%。这明显低于更广泛行业预期的 132% 的年增长率。</p>
</div><p>In light of this, it's understandable that XOMA Royalty's P/S sits below the majority of other companies. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.</p>
<div class="lb-trans"><p>鉴于此，XOMA Royalty 的市销率低于大多数其他公司是可以理解的。似乎大多数投资者预计未来增长有限，因此只愿意为该股票支付较低的价格。</p>
</div><h2>The Final Word</h2>
<div class="lb-trans"><h2>最后的总结</h2>
</div><p>While the price-to-sales ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of revenue expectations.</p>
<div class="lb-trans"><p>虽然市销率不应成为你是否购买股票的决定性因素，但它是收入预期的一个相当有效的晴雨表。</p>
</div><p>We've established that XOMA Royalty maintains its low P/S on the weakness of its forecast growth being lower than the wider industry, as expected. At this stage investors feel the potential for an improvement in revenue isn't great enough to justify a higher P/S ratio. The company will need a change of fortune to justify the P/S rising higher in the future.</p>
<div class="lb-trans"><p>我们已经确定，XOMA Royalty 维持其低市销率是因为其预测增长低于更广泛行业的预期。在这个阶段，投资者认为收入改善的潜力不足以证明更高的市销率。公司需要运气的改变才能在未来证明市销率的上升是合理的。</p>
</div><p>It is also worth noting that we have found <strong>2 warning signs for XOMA Royalty</strong> that you need to take into consideration.</p>
<div class="lb-trans"><p>还值得注意的是，我们发现 <strong>XOMA Royalty 有 2 个警示信号</strong>，你需要考虑。</p>
</div><p>If strong companies turning a profit tickle your fancy, then you'll want to check out this <strong>free</strong> list of interesting companies that trade on a low P/E (but have proven they can grow earnings).</p>
<div class="lb-trans"><p>如果你对盈利的强大公司感兴趣，那么你会想查看这份 <strong>免费</strong> 的有趣公司名单，这些公司以低市盈率交易（但已证明它们能够增长盈利）。</p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>国防和灾难的移动基础设施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人型的。它是完全自主的塔楼，在 30 分钟内提供 5G、ISR 和雷达，随时随地。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 赞助</p>
</div>

投资者看不到标记临床研究公司（纳斯达克股票代码：XOMA）隧道尽头的曙光